Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Recombinant virus encoding one or more heterologous proteins...
Reexamination Certificate
2008-04-30
2010-02-16
Salimi, Ali R. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Recombinant virus encoding one or more heterologous proteins...
C435S320100
Reexamination Certificate
active
07662395
ABSTRACT:
The present invention is a composition of recombinant virus which has incorporated into its genome or portion thereof a gene encoding an antigen to a disease causing agent and a recombinant virus which has incorporated into its genome or portion thereof a gene encoding an immunostimulatory molecule(s) for the purpose of stimulating an immune response against the disease causing agent. Methods of treatment of diseases such as cancer and diseases caused by pathogenic microorganisms is provide using the composition.
REFERENCES:
patent: 4690915 (1987-09-01), Rosenberg
patent: 5126132 (1992-06-01), Rosenberg
patent: 5206353 (1993-04-01), Berger et al.
patent: 5738852 (1998-04-01), Robinson et al.
patent: 5833975 (1998-11-01), Paoletti et al.
patent: 6045802 (2000-04-01), Schlom et al.
patent: 7211432 (2007-05-01), Schlom et al.
patent: 2004/0091995 (2004-05-01), Schlom et al.
patent: WO 91/02805 (1991-03-01), None
patent: WO 92/19266 (1992-11-01), None
patent: WO 92/20356 (1992-11-01), None
patent: WO 94/16716 (1994-08-01), None
patent: WO 94/24267 (1994-10-01), None
patent: WO 95/09241 (1995-04-01), None
Anichini et al., “Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients,”J. Exp. Med., 177 (4), 989-998 (1993).
Arlen et al., “A novel ELISPOT assay to enhance detection of antigen-specific T cells employing antigen-presenting cells expressing vector-driven human B7-1,”J. Immunol. Methods, 279 (1-2), 183-192 (2003).
Azuma et al., “B70 antigen is a second ligand for CTLA-4 and CD28,”Nature, 366 (6450), 76-79 (1993).
Balloul et al., “Recombinant MUC 1 vaccinia virus: a potential vector for immunotherapy of breast cancer,”Cell. Mol. Biol., 40 (Suppl. 1), 49-59 (1994).
Bei et al., “Enhanced immune responses and anti-tumor activity by baculovirus recombinant carcinoembryonic antigen (CEA) in mice primed with the recombinant vaccinia CEA,”J. Immunother., 16 (4), 275-282 (1994).
Bei et al., “Serological and biochemical characterization of recombinant baculovirus carcinoembryonic antigen,”Mol. Immunol., 31 (10), 771-780 (1994).
Brichard et al., “The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas,”J. Exp. Med., 178 (2), 489-495 (1993).
Bronte et al., “IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases,”J. Immunol., 154 (10), 5282-5292 (1995).
Chen et al., “Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity,”J. Exp. Med., 179 (2), 523-532 (1994).
Chen et al., “Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4,”Cell, 71 (7), 1093-1102 (1992).
Chen et al., “Costimulation of T cells for tumor immunity,”Immunol. Today, 14 (10), 483-486 (1993).
Cochran et al., “In vitro mutagenesis of the promoter region for a vaccinia virus gene: evidence for tandem early and late regulatory signals,”J. Virol., 54 (1), 30-37 (1985).
“Current Protocols in Molecular Bioloav. Generation of Recombinant Vaccinia Viruses,” 2, 16.17.1-6.17.16 (1994).
Döhring et al., “T-helper- and accessory-cell-independent cytotoxic responses to human tumor cells transfected with a B7 retroviral vector,”Int J. Cancer, 57 (5), 754-759 (1994).
D'Urso et al., “Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression,”J. Clin. Invest., 87(1), 284-292 (1991).
“Expression of Proteins in Mammalian Cells Using Vaccinia Viral Vectors, Overview of the Vaccinia Virus Expression System,”Current Protocols in Mol. Bio., Sect. IV, Unit 16.15-16.19.9 (1991).
Flexner et al., “Expression of Human Interleukin-2 by Live Recombinant Virus,”Vaccines, 87, 380-383 (1987).
Freeman et al., “B7.1, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells,”J. Immunol., 143 (8), 2714-2722 (1989).
Freeman et al., “Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation,”Science, 262 (5135), 909-911(1993).
Freeman et al., “Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice,”Science, 262 (5135), 907-909 (1993).
Freeman et al., “Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7,”J. Exp. Med., 174 (3), 625-631 (1991).
Gaugler et al., “Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes,”J. Exp. Med., 179 (3), 921-930 (1994).
Hathcock et al., “Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function,”J. Exp. Med., 180 (2), 631-640 (1994).
Hazama et al., “Adjuvant-independent enhanced immune responses to recombinant herpes simlex virus type 1 glycoprotein D by fusion with biologically active interleukin-2,”Vaccine, 11(6), 629-636 (1993).
Hellstrom et al., “On the role of costimulation in tumor immunity,”Ann. N. Y. Acad. Sci., 690, 225-231 (1993).
Hellstrom et al., “Tumor immunology: an overview,”Ann. N. Y. Acad. Sci., 690, 24-31 (1993).
Hinuma et al., “A novel strategy for converting recombinant viral protein into high immunogenic antigen,”FEBS Lett., 288 (1-2), 138-142 (1991).
Hodge et al., “Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules,”Cancer Res., 54 (21), 5552-5555 (1994).
Hodge et al., “Admixture of a recombinant vaccinia virus containing the gene for the costimulatory molecule B7 and a recombinant vaccinia virus containing a tumor-associated antigen gene results in enhanced specific T-cell responses and antitumor immunity,”Cancer Res., 55(16), 3598-3603 (1995).
June et al., “The B7 and CD28 receptor families,”Immunol Today, 15 (7), 321-331 (1994).
Kantor et al., “Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine,”J. Natl. Cancer Inst., 84 (14), 1084-1091 (1992).
Kantor et al., “Immunogenicity and safety of a recombinant vaccinia virus vaccine expressing the carcinoembryonic antigen gene in a nonhuman primate,”Cancer Res., 52 (24), 6917-6925 (1992).
Karupiah et al., “Recombinant vaccine vector-induced protection of athymic, nude mice from influenza A virus infection. Analysis of protective mechanisms,”Scand. J. Immunol., 36 (1), 99-105 (1992).
Kaufman et al., “A recombinant vaccinia virus expressing human carcinoembryonic antigen (CEA),”Int. J. Cancer., 48(6), 900-907 (1991).
Kawakami et al., “Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor,”PNAS, 91 (9), 3515-3519 (1994).
Kawakami et al., “Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes,”J. Exp. Med., 180 (1), 347-352 (1994).
Kawakami et al., “Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection,”PNAS, 91(14), 6458-6462 (1994).
Li et al., “Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma,”J. Immunol., 53 (1), 421-428 (1994).
Lindley et al., “Construction and characterization of adenovirus co-expressing hepatitis B virus surface antigen and interleukin-6,”Gene, 138 (1-2), 165-170 (1994).
Marincola et al., “Loss of HLA haplotype and B locus down-regulation in melanoma cell lines,ȁ
Hodge James W.
Kantor Judith
Schlom Jeffrey
Leydig , Voit & Mayer, Ltd.
Salimi Ali R.
The United States of America as represented by the Department of
LandOfFree
Method of enhancing a targeted immune response against tumors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of enhancing a targeted immune response against tumors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of enhancing a targeted immune response against tumors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4231170